Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 107 for:    Recruiting, Not yet recruiting, Available Studies | (idiopathic pulmonary fibrosis)

A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03832946
Recruitment Status : Recruiting
First Posted : February 6, 2019
Last Update Posted : February 22, 2019
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
Galecto Biotech AB

Brief Summary:
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis (IPF) Drug: TD139 Drug: Placebo Phase 2

Detailed Description:
This study is designed to evaluate the efficacy and safety of TD139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. Subjects will continue on their existing standard of care (SoC), including pirfenidone or nintedanib. Two doses of TD139, each given once per day, will be compared to placebo. A follow up period of up to 52 weeks, where the subjects remain on their designated treatment, will provide valuable information on the longer-term safety of TD139 in IPF.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

All subjects eligible for the study will be randomised into one of the three treatment arms:

A. TD139 10 mg once a day B. TD139 3 mg once a day C. TD139 Placebo once a day

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This study is a double-blind study. The blinding will be maintained throughout the study, including the follow up period.
Primary Purpose: Treatment
Official Title: GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks
Actual Study Start Date : February 19, 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021


Arm Intervention/treatment
Experimental: A. TD139 10 mg once a day
Inhalation of TD139
Drug: TD139
TD139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.

Experimental: B. TD139 3 mg once a day
Inhalation of TD139
Drug: TD139
TD139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.

Placebo Comparator: C. TD139 Placebo once a day
Inhalation of TD139 Placebo
Drug: Placebo
Placebo is administered as inhalation once a day




Primary Outcome Measures :
  1. Annual rate of decline in Forced Vital Capacity (FVC) [ Time Frame: 52 weeks ]
    Efficacy of TD139 as measured by the annual rate of decline in FVC expressed in mL


Secondary Outcome Measures :
  1. Absolute decline in FVC >10% [ Time Frame: 52 weeks ]
    Proportion of subjects with an absolute decline from baseline in FVC (% predicted) of > 10%

  2. Time to first hospitalization [ Time Frame: 52 weeks ]
    Time to first hospitalization related to Idiopathic Pulmonary Fibrosis (IPF), including acute exacerbation of IPF expressed in days

  3. Time to death [ Time Frame: 52 weeks ]
    Time to death from all-causes, respiratory-related causes and/or caused by IPF expressed in days


Other Outcome Measures:
  1. Absolute decline in FVC >5% [ Time Frame: 52 weeks ]
    Percentage of subjects with an absolute decline from baseline in FVC (% predicted) of > 5%

  2. 6-minute walk test (6MWT) distance [ Time Frame: 52 weeks ]
    Change from baseline in distance walked (metres) over 6 minutes

  3. Diffusion capacity of the lung for carbon monoxide (DLCO) [ Time Frame: 52 weeks ]
    Change from baseline in DLCO, corrected for Hemaglobin (mmol/min/kPa)

  4. Assessment of Dyspnea using the University of California San Diego - Shortness of Breath Questionnaire (UCSD - SOBQ) [ Time Frame: Weeks 12, 26 and 52 ]
    Change from baseline in UCSD - SOBQ Scored from 0-120 where a higher score indicates worse dyspnea

  5. Assessment of Health Related Quality of Life (HRQoL) using the Short-Form 36-Item Health Survey (SF-36) [ Time Frame: Weeks 12, 26 and 52 ]
    The Medical Outcomes SF-36 It is a self-administered questionnaire of 36-items measuring eight dimensions of general HRQoL: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). In addition to scores for individual dimensions, two summary scores assessing physical and mental dimensions of health and well-being can also be calculated: Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score, respectively. A higher score indicates a more favourable state of health

  6. Assessment of Respiratory Related Quality of Life using the St. George`s Respiratory Questionnaire (SGRQ) [ Time Frame: Weeks 12, 26 and 52 ]
    Change from baseline in the SGRQ total score. The SGRQ is a 50-item questionnaire split into three domains: symptoms, activity and impact. Weighting of both individual domains and the total score produces a range from 0 to 100, with higher scores indicating a poorer health-related quality of life.

  7. Frequency of Adverse Events (AE) or Serious Adverse Events (SAE) [ Time Frame: 52 weeks ]
    Percentage of subjects with Adverse Events (AE) or Serious Adverse Events (SAE)

  8. Time to hospitalization [ Time Frame: 52 weeks ]
    Time in days to first hospitalization - both from respiratory causes and all causes

  9. Time to initiation of pirfenidone or nintedanib treatment [ Time Frame: 52 weeks ]
    Time in days to initiation of pirfenidone or nintedanib treatment in subjects not treated with pirfenidone or nintedanib at time of enrolment

  10. Time to termination of pirfenidone or nintedanib treatment [ Time Frame: 52 weeks ]
    Time in days to termination of pirfenidone or nintedanib treatment for subjects treated with pirfenidone or nintedanib at time of enrolment

  11. Annual rate of decline in FVC in subjects never treated with pirfenidone or nintedanib [ Time Frame: 52 weeks ]
    Change in FVC expressed in mL for subjects who have never been treated with pirfenidone or nintedanib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects aged ≥ 40 years of age with a diagnosis of IPF established during the previous three years according to ATS/ERS/Fleischner criteria.
  2. Lung function parameters as follows:

    1. Forced Vital Capacity (FVC) > 45% of the predicted value at screening
    2. Diffusion lung capacity for carbon monoxide (DLCO) (corrected for Hb) of 30% to 79% of the predicted value at screening
  3. Any existing Standard of Care (SoC) treatment (e.g. pirfenidone or nintedanib) must be deemed as stable before randomization
  4. Subjects must sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures.

Exclusion Criteria:

  1. Currently has significant airways obstruction: Forced Expiratory Volume in 1 s (FEV1)/Forced Vital Capacity (FVC) ratio of < 0.7 at screening.
  2. Has clinical evidence of active infection, including, but not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, and cellulitis.
  3. Has a history of malignancy within the last 2 years with the exception of basal cell carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or managed by observation.
  4. Has any condition other than IPF that, in the opinion of the investigator, is likely to result in the death of the subject within the next 2 years.
  5. Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial
  6. Is likely to receive lung transplantation within the next 12 months.
  7. Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil, azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary hypertension (e.g., bosentan), and or investigational therapy for idiopathic pulmonary fibrosis (IPF) or administration of such therapeutics within 4 weeks of initial screening (or 5 half-lives, whichever is longer). A current dose of less than or equal to 15 mg/day of prednisone or its equivalent is acceptable if the dose is anticipated to remain stable during the study.
  8. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous six months, including, but not limited to, the following:

    1. Unstable angina pectoris or myocardial infarction, or percutaneous coronary intervention within the last 6 months
    2. Congestive heart failure requiring hospitalization
    3. Uncontrolled clinically significant arrhythmias
  9. If female, the subject is pregnant or lactating or intending to become pregnant before participating in this study during the study and within (5 half- lives plus 30 days) after last dose of the study drug; or intending to donate ova during such time period.
  10. Woman considered to be of childbearing potential who do not use highly effective birth control methods during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03832946


Contacts
Layout table for location contacts
Contact: Chief Medical Officer, MD, PhD +442037418183 Clinicaltrials@galecto.com

Locations
Layout table for location information
United States, Alabama
SEC Clinical Research Recruiting
Andalusia, Alabama, United States, 36420-5310
Contact: Robert Garver, MD         
Sponsors and Collaborators
Galecto Biotech AB
Syneos Health
Investigators
Layout table for investigator information
Principal Investigator: Toby Maher, MD, PhD Imperial College London

Layout table for additonal information
Responsible Party: Galecto Biotech AB
ClinicalTrials.gov Identifier: NCT03832946     History of Changes
Other Study ID Numbers: GALACTIC-1
2018-002664-73 ( EudraCT Number )
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galecto Biotech AB:
TD139
Idiopathic pulmonary fibrosis
Galectin-3 inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial